Overview
Quick answer
In Australia, a homocysteine blood test measures an amino acid produced when your body processes methionine from protein, reported in µmol/L after a 12 hour fast (RCPA Manual, reviewed 2 January 2024). The RCPA example interval is 5 to 15 µmol/L; a fasting result under 10 µmol/L is desirable if you already have vascular disease. Hemexa's own optimal band is stricter, 5 to 9 µmol/L, because that is longevity-focused company policy, not a population reference interval.
High homocysteine is linked to heart attack and stroke in large observational studies, which is why a high result is worth explaining and addressing: B12, folate, kidney function, sleep, and smoking are the usual places to look. Correcting a genuine B12 or folate shortfall is appropriate care in its own right. The narrower question is whether giving B-vitamin supplements as a population heart-prevention strategy cuts heart attacks, and large trials found it does not. That is why Pathology Tests Explained (11 April 2026) does not recommend homocysteine as routine heart screening, and why it is not in the 2023 Australian cardiovascular risk calculator. Hemexa still runs it annually with B12 and folate as a functional marker, not as a substitute for lipids or blood pressure.
Overview
Key takeaways
Australian reports use µmol/L. The RCPA example range is 5 to 15 µmol/L; labs are not fully harmonised, so use the interval on your report (Pathology Tests Explained). Hemexa's optimal band (5 to 9 µmol/L) is stricter because it is longevity-focused company policy, not an RCPA rule.
If established vascular disease is already present, RCPA says a fasting result under 10 µmol/L is desirable. That is a commentary line, not a statin-style treatment target.
RCPA asks for a 12 hour fast (EDTA or lithium heparin). Some Australian lab information sheets say fasting is not required. Follow the request form; Hemexa members fast because the baseline request is mixed.
Homocysteine is recycled using B12, folate (B9), and B6 as cofactors. A high result is often an early sign those pathways are short, sometimes before a vitamin level looks frankly low.
High homocysteine is linked to heart attack and stroke in observational studies, so take a high result seriously and find the cause. B-vitamin supplements used as a standalone heart-prevention strategy have not reduced heart attacks or death in large trials (HOPE-2; Cochrane 2017, 15 trials, 71,422 people), though a small stroke signal exists. That null result is about supplement protocols, not about whether correcting a genuinely short B12 or folate pathway is worthwhile, and it is not licence to ignore a high result.
A separate Oxford trial in older people with mild cognitive impairment (VITACOG, PLoS ONE 2010) found B-vitamin homocysteine-lowering slowed brain atrophy by about 30% overall, and about 53% when baseline homocysteine was above 13 µmol/L. That is one trial with a subgroup effect, not an RACGP-endorsed reason to test every adult.
Medicare does not fund homocysteine as routine heart screening. Item 66839 is a same-episode reflex when B12 is inconclusive; item 66842 is a follow-up item with listed criteria (fee $23.60).
MTHFR gene testing is not recommended in routine Australian general practice (RACGP). Measure homocysteine in blood if the clinical question is the metabolite.
Rare homocystinuria is a different disease. Australian newborn screening usually measures methionine, not homocysteine, and can miss milder B6-responsive forms.
Sleep disruption and long-term night shift work are associated with higher homocysteine in observational studies. Chronic stress may contribute, with thinner human evidence than B12 or folate. Check vitamins and kidney function first. Restoring sleep is good health advice; it is not a proven homocysteine-lowering trial endpoint.
Hemexa measures homocysteine annually on the membership baseline, with B12 and folate on the same panel. Active B12 is an add-on, not membership. MMA is not currently in the Hemexa catalogue.
Basics
What homocysteine measures
Homocysteine is an amino acid produced when your body uses methionine, an essential amino acid from dietary protein. It is not a vitamin level and it is not cholesterol.
Total homocysteine (tHcy) on the report is the usual lab number: free plus protein-bound species after the sample is reduced in the laboratory.
Normally kept low
Healthy cells recycle homocysteine through remethylation back to methionine or push it down the transsulfuration pathway toward cysteine. When those routes are slow, the level in blood rises.
A signal, not a diagnosis
High circulating homocysteine means recycling is slow, cofactor intake or absorption is low, the kidney is not clearing it, or (rarely) an enzyme is missing. It is also linked to heart attack and stroke in observational studies, and RCPA lists diagnosis of homocystinuria and detection of mild hyperhomocysteinaemia among its clinical applications. A high result is a signal to explain, not a diagnosis on its own.
Not routine screening for every adult
Australian patient information (Pathology Tests Explained, 2026) does not recommend homocysteine as a routine add-on to heart-risk screening for every asymptomatic adult. That is a screening rule, not a claim that a high result is harmless. It is most useful when B12, folate, or related symptoms need clarification, and when a previously high result is being tracked.
A single homocysteine result is a biochemical clue. It belongs in context with B12, folate, kidney function, medicines, and cardiovascular risk factors your clinician already tracks.
Mechanism
How the methionine cycle works
Homocysteine sits in the middle of the methionine cycle. Two main routes metabolise it: remethylation and transsulfuration.
Remethylation (back to methionine)
Methionine synthase (MTR) converts homocysteine to methionine using methylcobalamin (vitamin B12) and 5-methyl-THF from folate. When B12 or folate is short, this route stalls and homocysteine accumulates. Liver and kidney also remethylate via BHMT, using betaine instead of B12 and folate; that is why betaine is used in classical homocystinuria, not as a GP supplement protocol.
Transsulfuration (toward cysteine)
Cystathionine beta-synthase (CBS) sends homocysteine toward cystathionine and cysteine. Vitamin B6 is the cofactor here. B6 deficiency can raise homocysteine even when B12 and folate look adequate.
A recent protein meal adds methionine substrate, which is one reason RCPA specifies a 12 hour fast before collection.
Kidney disease raises homocysteine through reduced clearance, not only vitamin shortage. A high result in chronic kidney disease is not automatically fixed with a B-vitamin supplement.
A methionine loading test (oral methionine at 100 mg/kg) is a specialist metabolic protocol listed in the RCPA Manual. It is not a GP or membership screening test.
Reading your results
How to read an Australian report
Australian pathology reports label the line Homocysteine, tHcy, or Total homocysteine, always in µmol/L. Do not mix US mg/L conversions into the same discussion.
Reference intervals vary between laboratories and analysers. Pathology Tests Explained (11 April 2026) says to use the range printed on the same report, not a generic internet number.
Homocysteine / tHcy / Total homocysteine
The main result in µmol/L. Compare to this laboratory's reference interval, not a blog post from another country.
RCPA example interval: 5 to 15 µmol/L
The RCPA Manual cites 5 to 15 µmol/L as an example adult interval (last reviewed 2 January 2024). Your lab may print a different upper or lower bound.
Vascular-disease comment: fasting under 10 µmol/L
If established vascular disease is already present, RCPA says a desirable fasting concentration is under 10 µmol/L. That is commentary on the report, not a universal treatment target.
H or L flags
A flag outside the printed interval is a prompt for clinical review, not a diagnosis on its own (Pathology Tests Explained).
| Band | Range | What it means |
|---|---|---|
| RCPA example interval | 5 to 15 µmol/L | Population reference interval on many Australian reports (RCPA Manual, reviewed 2 January 2024). |
| Vascular disease comment | Fasting under 10 µmol/L desirable | When established vascular disease is already present (RCPA commentary, not a universal treatment target). |
| Hemexa preventative band | 5 to 9 µmol/L optimal | Longevity-focused company policy layered on the pathology partner interval, not an RCPA rule. |
Hemexa preventative band (company policy)
Hemexa's own clinical policy, layered on Healius Pathology's reference interval, currently uses an optimal band of 5 to 9 µmol/L and a wider watch band of 4 to 14 µmol/L. That band is stricter than the RCPA example of 5 to 15 µmol/L because it is longevity-focused company policy, not because RCPA or Medicare set a tighter screening rule. It should not be read as a national medical standard.
Reference interval vs preventative target
A result inside the lab's 5 to 15 µmol/L example can still sit above Hemexa's preventative band. The difference between a population reference interval and a preventative target is explained on the reference range vs optimal range guide.
Trend two or three annual results on the same assay where possible. A single point is hard to interpret when collection fasting or preanalytical handling differed between draws.
For the wider reference-interval vs preventative-target distinction, see the reference range vs optimal range guide.
Collection
Fasting and collection
The RCPA Manual asks for 5 mL EDTA or lithium heparin after a 12 hour fast, or after an oral methionine load in selected metabolic work-ups. Methods include HPLC and immunoassay (last reviewed 2 January 2024).
Not every Australian lab sheet agrees. Canberra Health Services / ACT Pathology (2024) states fasting is not necessary for homocysteine, with centrifugation within two hours. Follow the pathology request form or collection centre instructions. Hemexa members still fast because glucose, insulin, homocysteine, and iron studies share the baseline request.
Preanalytical handling matters. Unseparated blood at room temperature lets cells keep releasing homocysteine (about 1 µmol/L per hour in the UK ACB methods catalogue note). Collectors process the tube; you cannot correct a delayed draw at home.
For the mixed-form fasting rule on Hemexa panels, see the fasting blood test guide.
Heart and stroke
Homocysteine and heart disease
High homocysteine is linked to heart attack and stroke, and a high result is worth taking seriously for that reason alone.
A 2002 individual-participant meta-analysis of 30 observational studies found higher circulating homocysteine associated with ischaemic heart disease and stroke (Homocysteine Studies Collaboration, JAMA 2002). In the prospective studies, after adjustment for known risk factors, a 25% lower usual homocysteine level (about 3 µmol/L) was associated with 11% lower ischaemic heart disease risk and 19% lower stroke risk. The authors called it a modest independent predictor in healthy populations. Modest is not zero.
The next question is narrower: does giving B-vitamin supplements as a population heart-prevention strategy actually cut heart attacks? Large trials (HOPE-2; Cochrane 2017) found it did not, with only a modest reduction in stroke. That is why Pathology Tests Explained (11 April 2026) does not recommend homocysteine for routine cardiovascular risk assessment, and why it is absent from the 2023 Australian risk calculator. Those are decisions about screening and supplement protocols, not findings that high homocysteine is harmless or that correcting a genuine B12 or folate shortfall is unhelpful.
The observational link (JAMA 2002)
The Homocysteine Studies Collaboration pooled 30 prospective and retrospective studies (5,073 ischaemic heart disease events and 1,113 stroke events). After adjustment in the prospective studies, a 25% lower usual homocysteine level (about 3 µmol/L) was associated with an 11% lower ischaemic heart disease risk (OR 0.89, 95% CI 0.83 to 0.96) and a 19% lower stroke risk (OR 0.81, 95% CI 0.69 to 0.95). The paper itself frames this as a modest independent predictor, and that modest, real association is the reason a high personal result is still worth explaining.
HOPE-2 (NEJM 2006)
In 5,522 adults aged 55 or older with vascular disease or diabetes, folic acid, vitamin B6, and vitamin B12 for about five years lowered mean homocysteine by 2.4 µmol/L. The primary composite of cardiovascular death, myocardial infarction, and stroke was 18.8% on treatment versus 19.8% on placebo (relative risk 0.95, P=0.41). Stroke risk was lower (RR 0.75); hospitalisations for unstable angina were more frequent (RR 1.24). HOPE-2 tested whether supplementation prevents heart attacks in people who already have vascular disease, not whether a high result should be ignored or a genuine B12 or folate shortfall left uncorrected.
Cochrane review (2017)
Fifteen randomised trials with 71,422 participants found B-vitamin therapy given to lower homocysteine did not reduce myocardial infarction (RR 1.02) or all-cause death (RR 1.01), with stroke risk modestly lower (RR 0.90). Evidence was current to June 2017. With death unchanged and stroke slightly improved, there is no signal here that B-vitamin supplementation is unsafe, only that it does not work as population heart-attack prevention.
2023 Australian CVD guideline
The Heart Foundation-led calculator (Nelson et al., MJA 2024) does not include homocysteine as an input. Treatment decisions still flow from five-year absolute risk, lipids, blood pressure, diabetes, and smoking.
VITACOG (PLoS ONE 2010)
In 271 people aged 70 or older with mild cognitive impairment, folic acid, vitamin B6, and vitamin B12 for two years were tested against placebo. Among 168 who completed MRI, mean whole-brain atrophy was 0.76% per year on treatment versus 1.08% on placebo (about 30% slower, P=0.001). In those with baseline homocysteine above 13 µmol/L, atrophy was about 53% slower. There was no atrophy effect in the lowest quartile (9.5 µmol/L or under). This is a single-centre trial in a selected MCI group, with the largest effect in a subgroup. It is not an RACGP-endorsed indication for testing, and it does not overturn the cardiovascular findings above.
A high homocysteine result is worth explaining (B12, folate, kidney, medicines, sleep), and correcting a documented shortfall is appropriate care in its own right. It still does not replace lipids, ApoB, blood pressure control, or smoking cessation, and it is not a reason to start an unsupervised supplement protocol labelled as heart-attack prevention. VITACOG does not change that sequence: one MCI trial is not an RACGP-endorsed indication for testing, and it is not a licence to self-prescribe B vitamins for cognition.
For what the Australian risk calculator does include, see the high cholesterol blood tests guide.
B vitamins
B12, folate, and MMA
Pathology Tests Explained lists homocysteine most often to assess vitamin B12, folate, and less often vitamin B6. B6 is usually considered when B12 and folate look normal.
Australian B12 guidance reads total B12 in three bands; the indeterminate band (133 to 258 pmol/L in current Australian Prescriber guidance) is the usual trigger for active B12, MMA, or homocysteine follow-up. That pathway is covered on the vitamin B12 guide; this page owns the homocysteine assay itself.
MMA vs homocysteine
Methylmalonic acid (MMA) is more specific for B12 because it reflects methylmalonyl-CoA mutase activity. Homocysteine rises in both B12 and folate shortage. If only folate is low, MMA can stay normal while homocysteine rises.
MMA on usual pathology, not on Hemexa membership
MMA is a standard Australian pathology assay when a GP requests it, but it is not in the Hemexa marker catalogue. Do not assume membership includes MMA. Active B12 (holotranscobalamin) is available as a Hemexa add-on, not on the baseline panel.
On the Hemexa annual baseline
Homocysteine, vitamin B12, and folate are measured annually on the 76–80 marker baseline, not on the default six-month retest.
Causes
Common causes of a high result
Nutrients and absorption
- Low B12 or folate intake or absorption (see the vitamin B12 guide for grey-zone pathways)
- Vitamin B6 shortage when B12 and folate look normal
Kidney, lifestyle, and sleep
- Chronic kidney disease (reduced clearance)
- Smoking (Pathology Tests Explained)
- Short sleep (about 5 hours or less) is associated with higher serum homocysteine in US survey data (Chen et al., 2019)
- Long-term night shift work (about 10 years or more) is associated with higher rates of hyperhomocysteinaemia; shorter tenure is not, and not every night worker is high (Kang et al., 2019; Puttonen et al., 2010)
- Chronic psychological stress: plausible (glucocorticoids can slow the B6-dependent CBS pathway in animal studies); human data are thinner than for B12 or folate, and strongest in PTSD rather than ordinary job stress (de Vries et al., 2015)
- Delayed sample processing before centrifugation
Medicines and recreational exposure
- Some prescription medicines that affect B vitamins
- Recreational nitrous oxide, which inactivates B12 at the molecular level (covered on the B12 guide)
Rare metabolic disease
- Classical homocystinuria (CBS deficiency): eye, bone, and thrombosis risk with very high levels
- Australian newborn screening measures methionine on the heel-prick card; B6-responsive forms may be missed because methionine may not rise in the first weeks (Healthy WA)
Genetics
MTHFR without treating a gene
Common MTHFR gene variants are frequent in the population. RACGP does not recommend routine MTHFR gene testing in ordinary general practice because the result rarely changes management.
ACMG (2013) found MTHFR polymorphism testing has minimal clinical utility for thrombophilia work-ups; when clinically relevant, measure fasting total plasma homocysteine instead.
Blood test first
If the clinical question is the metabolite, measure homocysteine in blood. A common MTHFR variant with a normal homocysteine does not create a treatment plan.
If homocysteine is high
Work up B12, folate, kidney function, and medicines the same way regardless of genotype. This page does not describe gene-directed supplement stacks.
Hemexa genetics (high level)
Membership genetics can add context after the blood result, not instead of it. There is no public gene-directed supplement protocol on this site.
Severe MTHFR enzyme deficiency in infants is not the same as the common C677T polymorphism. Do not conflate a research gene variant with classical homocystinuria.
How to order
How Australians get the test
| Approach | Best for | Typical cost | Includes homocysteine? |
|---|---|---|---|
| GP B12 work-up (Medicare) | B12 grey zone, symptoms, or listed risk factors | Bulk-billed or low gap when eligible | Items 66839 or 66842 when criteria met |
| GP-ordered standalone homocysteine (private) | Targeted functional marker with GP oversight | Varies by lab; not routine heart screening | Yes, when added to the request |
| Private comprehensive panels | One-off cardiovascular or nutrient panels | Bundled in panel pricing | Sometimes included with B12 and folate |
| Membership platforms (e.g. Hemexa) | Annual homocysteine with B12, folate, and heart markers | ~$1,199/year (full membership) | Yes; homocysteine on the annual baseline among 76–80 signature markers |
Pathology in Australia requires an authorised request from a registered medical practitioner. Collection is through Healius Pathology collection at 2,000+ centres. Homocysteine is not funded as population heart screening under Medicare; see the Medicare blood tests guide for items 66838, 66839, and 66842.
FAQ
Frequently asked questions
- What is a homocysteine blood test in Australia?
- It measures total homocysteine in a blood sample, reported in µmol/L. Homocysteine is an amino acid your body makes while processing methionine from protein. Vitamins B12, folate, and B6 normally keep the level low. Australian labs may label the line Homocysteine, tHcy, or Total homocysteine.
- What is a normal homocysteine level in Australia?
- The RCPA Manual example interval is 5 to 15 µmol/L. If you already have vascular disease, RCPA says a fasting result under 10 µmol/L is desirable. Hemexa's own optimal band is stricter (5 to 9 µmol/L) because it is longevity-focused company policy, not an RCPA rule. Reference intervals vary between laboratories (Pathology Tests Explained, 11 April 2026), so use the range printed on your report. A flag is not a diagnosis.
- Do you need to fast for a homocysteine test?
- Usually yes, when the request follows RCPA: a 12 hour fast, water only. Some Australian lab sheets say fasting is not required. Follow the pathology request form or the collection centre. If the same form includes fasting glucose or insulin, you fast for the whole visit. Hemexa members should fast for baseline because those panels mix fasting and non-fasting assays.
- Does high homocysteine cause heart disease?
- No, B-vitamin supplements used as a population heart-prevention strategy have not reduced heart attacks or deaths in large trials (HOPE-2; Cochrane 2017, 15 trials, 71,422 people). High homocysteine is still linked to heart attack and stroke in observational studies, which is why a high result is worth explaining: B12, folate, kidney function, sleep, and smoking are the usual places to look. Correcting a genuine B12 or folate shortfall is appropriate care in its own right. That is why Australian patient information does not recommend the test as routine heart-risk screening, and why the 2023 CVD calculator does not use it. None of this means B12 or folate correction is pointless, or that a high result can be ignored.
- Why would homocysteine be high if my B12 looks normal?
- Total B12 can sit in the indeterminate band (133 to 258 pmol/L in current Australian guidance) while the enzymes are already short. Homocysteine (or MMA) can rise before the vitamin level looks frankly deficient. Folate shortage raises homocysteine even when B12 is adequate. Kidney disease, smoking, short sleep, long-term night shift work, delayed sample processing, and some medicines also raise the result. See the vitamin B12 guide for the grey-zone pathway.
- Should I get an MTHFR gene test instead?
- Not as a routine test. RACGP does not recommend MTHFR gene testing in ordinary general practice, because common variants are frequent and the result rarely changes management. If the clinical question is the metabolite, measure blood homocysteine. A common MTHFR variant with a normal homocysteine does not create a treatment plan.
- Does Medicare cover a homocysteine blood test?
- Not as routine heart screening. Medicare can cover homocysteine when it is used in the vitamin B12 pathway: item 66839 (same episode as 66838 if B12 is inconclusive or abnormal) or item 66842 for listed follow-up and risk-factor criteria (schedule fee $23.60). Outside those rules, the test may be privately billed. Membership panels that include homocysteine are private.
- How often should homocysteine be tested?
- There is no Red Book rule that every well adult needs yearly homocysteine. Clinically, it is repeated when B12 or folate status is being worked up, or when a clinician is tracking a previously high result. Hemexa membership includes it on the annual baseline, not on the default six-month retest, as company policy.
- Can stress or poor sleep raise homocysteine?
- They can be associated with a higher result. Homocysteine has a daily rhythm with a night-time peak (Lavie and Lavie, 2004). Long-term night shift work has been linked to higher rates of hyperhomocysteinaemia in observational studies, especially after many years of nights (Kang et al., 2019), and US survey data link sleep of about 5 hours or less with higher serum homocysteine (Chen et al., 2019). Chronic psychological stress has a plausible mechanism, and is elevated in PTSD even when B12, folate, and B6 look normal (de Vries et al., 2015); evidence for ordinary job stress is thinner. None of this replaces a B12, folate, and kidney work-up. Restoring sleep is still good advice.
- How do you lower homocysteine?
- To lower a high homocysteine result, correct the underlying cause first: treat genuine vitamin B12 or folate deficiency with your GP, improve kidney function where relevant, and stop smoking. Large trials show B-vitamin supplements do not prevent heart attacks in the general population, so do not self-prescribe a heart stack. MTHFR gene testing rarely changes management; measure blood homocysteine instead. Sleep and stress may contribute, but check B12, folate, and kidney function before attributing a high result to lifestyle alone.
How Hemexa fits
How Hemexa can help
Homocysteine is most useful on an annual trend line alongside B12 and folate, with the same mixed-form fast used for glucose and insulin on the baseline draw.
Homocysteine, B12, and folate on the annual baseline
Hemexa includes homocysteine, vitamin B12, and folate on the 76–80 marker annual baseline after the same mixed-form fast used for fasting glucose and fasting insulin. It is not on the default six-month retest.
µmol/L trends and company policy band
Results trend in µmol/L in the member app. Hemexa's preventative band (currently 5 to 9 µmol/L optimal, 4 to 14 µmol/L watch) is longevity-focused company policy layered on the pathology partner interval, not an RCPA rule.
GP-reviewed requests and Healius Pathology collection at 2,000+ centres
Hemexa coordinates authorised pathology requests and collection at 2,000+ centres nationwide through Healius Pathology, our only collection partner. Active B12 is an add-on when the grey-zone pathway needs it; MMA is not on the Hemexa panel.
Not a substitute for proven cardiovascular care
Homocysteine does not replace lipids, ApoB, hs-CRP, blood pressure management, or the Australian risk calculator. Hemexa does not prescribe B-vitamin protocols or replace your GP for deficiency or cardiovascular care.
Sources
References
Royal College of Pathologists of Australasia. Homocysteine (RCPA Manual, reviewed 2 January 2024). View source ↗
Pathology Tests Explained. Homocysteine (11 April 2026). View source ↗
The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002;288(16):2015-2022. View source ↗
The HOPE-2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. New England Journal of Medicine 2006;354:1567-1577. View source ↗
Martí-Carvajal AJ, Solà I, Lathyris D, Dayer M. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database of Systematic Reviews 2017. View source ↗